CompletedNCT02493868
A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression
Medication studyAges 18–64Multiple countries
Understand this study
Who was this study for?
Listed age limits: 18 years to 64 years.
- Listed locations
- Birmingham and 154 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateStarted: October 1, 2015
- Recruitment status
- Completed
- Enrollment listed in the registry
- 719
- Sponsor
- Janssen Research & Development, LLC
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, France, Canada, ...
- Age range
- From 18 Years to 64 Years
- Official registry ID
- NCT02493868
- Official title
Show the full official title
A Randomized, Double-blind, Multicenter, Active-Controlled Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Treatment-resistant Depression
Get this study by email
Recruitment & locations
CompletedBirmingham, United States · Little Rock, United States · Anaheim, United States
154 more locations
- Garden Grove, United States
- Glendale, United States
- Oakland, United States
- Orange, United States
- San Diego, United States
- San Marcos, United States
- San Rafael, United States
- Hartford, United States
- Bradenton, United States
- Gainesville, United States
- Miami, United States
- Orlando, United States
- Tampa, United States
- Atlanta, United States
- Chicago, United States
- Hoffman Estates, United States
- Joliet, United States
- Maywood, United States
- Schaumburg, United States
- Skokie, United States
- Prairie Village, United States
- Wichita, United States
- Lake Charles, United States
- Baltimore, United States
- Gaithersburg, United States
- Boston, United States
- New Bedford, United States
- Quincy, United States
- Watertown, United States
- Worcester, United States
- Rochester Hills, United States
- Minneapolis, United States
- O'Fallon, United States
- Saint Charles, United States
- Omaha, United States
- New York, United States
- Durham, United States
- Hickory, United States
- Oklahoma City, United States
- Media, United States
- Philadelphia, United States
- Scranton, United States
- Lincoln, United States
- Providence, United States
- Arlington, United States
- Austin, United States
- Dallas, United States
- Houston, United States
- Charlottesville, United States
- Waukesha, United States
- Aalst, Belgium
- Bruges, Belgium
- Brussels, Belgium
- Heusden-Zolder, Belgium
- Liège, Belgium
- Yvoir, Belgium
- Belo Horizonte, Brazil
- Curitiba, Brazil
- Fortaleza, Brazil
- Goiânia, Brazil
- Itapira, Brazil
- Passo Fundo, Brazil
- Porto Alegre, Brazil
- Rio de Janeiro, Brazil
- Santo André, Brazil
- São José do Rio Preto, Brazil
- São Paulo, Brazil
- Calgary, Canada
- Vancouver, Canada
- Kingston, Canada
- Ottawa, Canada
- Toronto, Canada
- Montreal, Canada
- Brno, Czechia
- Hostivice, Czechia
- Klecany, Czechia
- Kutná Hora, Czechia
- Litoměřice, Czechia
- Pilsen, Czechia
- Prague, Czechia
- Strakonice, Czechia
- Pärnu, Estonia
- Tallinn, Estonia
- Tartu, Estonia
- Clermont-Ferrand, France
- Douai, France
- Nantes, France
- Nîmes, France
- Paris, France
- Poitiers, France
- Toulon, France
- Berlin, Germany
- Cham, Germany
- Gelsenkirchen, Germany
- Halle, Germany
- Mainz, Germany
- Mittweida, Germany
- Pfaffenhofen, Germany
- Prien am Chiemsee, Germany
- Balassagyarmat, Hungary
- Budapest, Hungary
- Debrecen, Hungary
- Győr, Hungary
- Pécs, Hungary
- Sopron, Hungary
- Szeged, Hungary
- Szekszárd, Hungary
- Vác, Hungary
- Guadalajara, Mexico
- León, Mexico
- Mexico City, Mexico
- Monterrey, Mexico
- San Luis Potosí City, Mexico
- Bełchatów, Poland
- Bialystok, Poland
- Bydgoszcz, Poland
- Gdansk, Poland
- Leszno, Poland
- Lodz, Poland
- Lublin, Poland
- Pruszków, Poland
- Torun, Poland
- Tuszyn, Poland
- Warsaw, Poland
- Bratislava, Slovakia
- Liptovský Mikuláš, Slovakia
- Rimavská Sobota, Slovakia
- Rožňava, Slovakia
- Svidník, Slovakia
- Alcorcón, Spain
- Barcelona, Spain
- Palma, Spain
- Pamplona, Spain
- Ponferrada, Spain
- Sabadell, Spain
- Salamanca, Spain
- Vitoria-Gasteiz, Spain
- Lund, Sweden
- Skövde, Sweden
- Solna, Sweden
- Stockholm, Sweden
- Adana, Türkiye
- Ankara, Türkiye
- Bursa, Türkiye
- Denizli, Türkiye
- Istanbul, Türkiye
- Izmir, Türkiye
- Kucukcekmece/Istanbul, Türkiye
- Manisa, Türkiye
- Oanakkale, Türkiye
- Sakarya, Türkiye
- Samsun, Türkiye
- Czechia
- Türkiye
Questions about this study
Who is behind this study?
The study sponsor is Janssen Research & Development, LLC.
Did this study involve medication?
Yes. The study involved medication, including Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant), Sertraline (Oral Antidepressant) and Venlafaxine Extended Release (XR) (Oral Antidepressant).
Who was this study for?
Listed age limits: 18 years to 64 years.
